Medios AG Reports Revenue Growth in Q1 2024 and Confirms Yearly Targets

Medios AG, a leader in Specialty Pharma solutions in Germany, announced a 5.8% increase in revenue to €456.2 million for the first quarter of 2024. Despite significant operational activities, including the upcoming acquisition of Ceban Pharmaceuticals, the company confirmed its financial guidance for the year.

The company's EBITDA pre1 remained stable at €15.1 million. However, the Pharmaceutical Supply segment saw revenue rise by 8.9%, while the Patient-Specific Therapies segment experienced a revenue decline due in part to the sale of a subsidiary and regulatory price changes. Cash flow from operating activities significantly improved, turning positive at €43.4 million compared to a loss in the previous year.

Medios also declared the imminent closure of the Ceban acquisition, a move that aims to expand its market influence across Europe, particularly in the Netherlands, Belgium, and Spain. CEO Matthias Gaertner expressed optimism about the company's growth trajectory post-acquisition. For 2024, Medios expects revenues to reach between €1.9 billion and €2.1 billion, with forecast EBITDA pre1 between €82 million and €91 million.

The acquisition of Ceban is seen as a strategic expansion to create a leading European Specialty Pharma platform, indicating strong growth prospects for Medios AG going forward.